Abstract
Although increased levels of C-reactive protein have been linked to E therapy, the significance of this finding and whether it occurs with the selective ER modulators are un- known. Thirty-five healthy postmenopausal women were en- rolled in a placebo-controlled, two-period cross-over design trial to evaluate the effects of 0.625 mg oral conjugated E and 60 mg droloxifene, a structural analog of tamoxifen, on serum levels of C-reactive protein, IL-6, and endothelial cell adhe- sion molecules. E treatment resulted in 65.8% higher levels of C-reactive protein (P 0.0002) and 48.1% higher levels of IL-6 (P < 0.001), but also resulted in a 10.9% reduction in soluble E-selectin (P 0.002) and borderline reductions in vascular cell adhesion molecule-1. In contrast, droloxifene had no ef- fect on C-reactive protein and IL-6, but did produce a signif- icant 11% reduction in E-selectin (P < 0.00001). However, droloxifene also resulted in an 11.6% increase in vascular cell adhesion molecule-1 (P < 0.007). These data provide additional evidence of a proinflamma- tory effect of E that may have adverse cardiovascular conse- quences. However, these changes were also accompanied by a reduction in E-selectin, suggesting an antiinflammatory ef- fect at the level of the endothelium. The net clinical impact of these changes is not yet well established. In contrast, drolox- ifene had little or no proinflammatory effects on C-reactive protein and IL-6 and had mixed effects on endothelial adhe- sion molecules. This observation provides additional ratio- nale for continuing to evaluate the potential cardiovascular benefits of selective ER modulators. (J Clin Endocrinol Metab 86: 4216 - 4222, 2001)